US Family Health Plan Prior Authorization Request Form for atogepant (Qulipta)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Approval for initial is 6 months; for continuation therapy is indefinite.							
Step	Please complete patient and physician information (please print):						
.1	Patien	t Name: Phy	Physician Name:				
	Addres	ss:	Address:				
	Snone	or ID#	Phone #:				
	•		Secure Fax #:				
Step	Bate	. 5	ocure i ax ii.				
2	1.	Has the patient received this medication under the USFHP benefit in the last 6 months? Please choose "No" if the patient did not previously have a USFHP approved PA for Qulipta.	□ Yes	□ No			
			(subject to verification)	Proceed to question 4			
			Proceed to question 2				
	2.	Has the patient had a reduction in mean monthly headache days of greater than or equal to 50% relative to the pretreatment baseline (as shown by patient diary documentation or healthcare provider attestation)?	□ Yes	□ No			
			Sign and date below	Proceed to question 3			
	3.	Has the patient shown a clinically meaningful improvement in ANY of the following validated migraine-specific patient-reported outcome measures:	□ Yes	□ No			
			Sign and date below	STOP			
	0	Migraine Disability Assessment (MIDAS): reduction of greater than or equal to 5 points when baseline score is 11-20; reduction of greater than or equal to 30%		Coverage not approved			
		when baseline score is greater than 20;					
	0	Headache Impact Test (HIT-6): reduction of greater than or equal to 5 points; OR					
	0	Migraine Physical Functional Impact Diary (MPFID): reduction of greater than or equal to 5 points?					
	4.	Is the requested medication being used for prevention of episodic migraine?	□ Yes	□ No			
			Proceed to question 5	STOP			
				Coverage not approved			
	5.	Does the patient have episodic migraines at a rate of 4 to 7 migraine days per month for 3 months?	□ Yes	□ No			
			Proceed to question 6	Proceed to question 7			
	6.	Does the patient have at least moderate disability shown by Migraine Disability Assessment (MIDAS) Test score greater than 11 OR Headache Impact Test-6 (HIT-6) score greater than 50?	☐ Yes	□ No			
			Proceed to question 8	Proceed to question 7			

USFHP Prior Authorization Request Form for atogepant (**Qulipta**)

	7.	Does the patient have episodic migraine at a rate of at least 8 migraine days per month for 3 months?	☐ Yes Proceed to question 8	□ No STOP		
				Coverage not approved		
	8.	Does the patient have a contraindication to, intolerability to, or has failed a 2-month trial of at least ONE drug from TWO of the following migraine prophylactic drug classes:	☐ Yes Proceed to question 9	□ No STOP Coverage not approved		
	0	prophylactic antiepileptic medications: valproate, divalproic acid, topiramate;				
	0	prophylactic beta-blocker medications: metoprolol, propranolol, atenolol, nadolol, timolol;				
	0	prophylactic antide pressants: am itriptyline, duloxetine, nortriptyline, venlafaxine?				
	9.	 Does the patient have a contraindication to, intolerability to, or has failed a 2-month trial of at least ONE of the following CGRP injectable agents: erenumab-aooe (Aimovig), fremanezumab-vfrm (Ajovy), galcanezumab-gnlm (Emgality)? 	☐ Yes	□ No		
			Sign and date below	STOP		
				Coverage not approved		
Step 3	I certify the above is true to the best of my knowledge. Please sign and date:					
		Prescriber Signature	 Date			
				.[27 December 2021]		